APRI, FIB4, and Fibroscan as Predictors of early Hepatocellular Carcinoma Recurrence in patients underwent Thermal Ablation
Al-Dahshan, M., Baki, A., Ramadan, I., Aly, S., Rashwan, T., Abdelsalam, A. (2645). APRI, FIB4, and Fibroscan as Predictors of early Hepatocellular Carcinoma Recurrence in patients underwent Thermal Ablation. EKB Journal Management System, 2024(1), -. doi: 10.58675/2682-339X.2269
Magdy Abd-Alkareem Al-Dahshan; Amin Abdel Baki; Ibrahim Ghouniem Ramadan; Sherif Farouk Aly; Tamer Hassan Rashwan; Abdelsalam Saqr Abdelsalam. "APRI, FIB4, and Fibroscan as Predictors of early Hepatocellular Carcinoma Recurrence in patients underwent Thermal Ablation". EKB Journal Management System, 2024, 1, 2645, -. doi: 10.58675/2682-339X.2269
Al-Dahshan, M., Baki, A., Ramadan, I., Aly, S., Rashwan, T., Abdelsalam, A. (2645). 'APRI, FIB4, and Fibroscan as Predictors of early Hepatocellular Carcinoma Recurrence in patients underwent Thermal Ablation', EKB Journal Management System, 2024(1), pp. -. doi: 10.58675/2682-339X.2269
Al-Dahshan, M., Baki, A., Ramadan, I., Aly, S., Rashwan, T., Abdelsalam, A. APRI, FIB4, and Fibroscan as Predictors of early Hepatocellular Carcinoma Recurrence in patients underwent Thermal Ablation. EKB Journal Management System, 2645; 2024(1): -. doi: 10.58675/2682-339X.2269

APRI, FIB4, and Fibroscan as Predictors of early Hepatocellular Carcinoma Recurrence in patients underwent Thermal Ablation

Al-Azhar International Medical Journal
Volume 2024, Issue 1, January 2024  XML
DOI: 10.58675/2682-339X.2269
View on SCiNiTO View on SCiNiTO
Authors
Magdy Abd-Alkareem Al-Dahshan1; Amin Abdel Baki2; Ibrahim Ghouniem Ramadan3; Sherif Farouk Aly4; Tamer Hassan Rashwan5; Abdelsalam Saqr Abdelsalam6
1Professor and Head of Internal Medicine Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
2Professor and Head of Gastroenterology and Hepatology Department, National Hepatology and Tropical Medicine Research Institute, Al-Azhar University, Cairo, Egypt
3Assistant Professor of Internal Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
4Assistant Professor and Consultant of Gastroenterology and Hepatology, Air force Hospital, Military Medical Academy, Cairo, Egypt
5Lecturer of internal Medicine Departmen, Faculty of Medicine, Al-Azhar University, Assuit, Egypt;
6MBBcH of internal Medicine Departmen, Faculty of Medicine, Al-Azhar University, Assuit, Egypt
Abstract
Background: Liver malignancies are a significant global health concern, ranking fifth in terms of incidence and fourth in terms of cancer-related mortality. Hepatocellular carcinoma (HCC) is the most common kind of liver cancer, accounting for around 90% of cases. Notably, the incidence of HCC has shown a substantial increase of 75% between 1990 and 2015. Aim & Objectives: To assess the outcome of thermal ablation therapy in patients with early HCC. Evaluate validation of APRI, FIB4, and Fibroscan in predicting early HCC recurrence following thermal ablation. Detect cut off point of this values in predicting early HCC recurrence following thermal ablation. Subjects & Methods: Current study was done on 50 HCC patients who undergone percutaneous TA for treatment naive HCC. Their mean age was 52-76 years with a mean of 61.5±7.41 years, 32 (64%) males and 18 (36%) females with male predominance (1:1.8 female to male ratios). Result: The Fibroscan has been identified as a highly dependable noninvasive method for evaluating liver fibrosis. However, its utilization is constrained due to its elevated cost and limited accessibility in smaller urban areas. Conclusion: The Fibroscan has been identified as a very dependable noninvasive method for evaluating liver fibrosis. However, due to its considerable expense and limited accessibility in smaller urban areas, the utilization of this tool is constrained.
Statistics
Article View: 20